Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS.
作者： Dionysis Papadatos-Pastos , Adam Januszewski , Angus Dalgleish
DOI: 10.1586/ERA.13.33
关键词:
摘要: The CNS is a common site of metastasis in patients with malignant melanoma. Locoregional control either surgery or radiotherapy first-line treatment for brain should they be suitable candidates. For those who are not and progress after previous treatment, there an unmet clinical need effective systemic therapies. Systemic cytotoxics, such as temozolamide fotemustine, have only modest activity, resulting median progression-free survival ranging from 1–2 months, metastatic melanoma to the brain. Newer treatments vemurafenib ipilimumab been approved melanoma, but evidence regarding their activity metastases inconclusive due limited access trials. This now being revised more data emerging supporting inclusion In this review, authors present efficacy sys...
expert-reviews.com参考文章(79)
Israel Vlodavsky, Yael Friedmann, Michael Elkin, Helena Aingorn, Ruth Atzmon, Rivka Ishai-Michaeli, Menachem Bitan, Orit Pappo, Tuvia Peretz, Israel Michal, Larissa Spector, Iris Pecker, Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nature Medicine. ,vol. 5, pp. 793- 802 ,(1999) , 10.1038/10518
David J. McConkey, Roy S. Herbst, Hiroki Kuniyasu, Corazon D. Bucana, Hisashi Shinohara, Darren W. Davis, Lee M. Ellis, Isaiah J. Fidler, Seiji Yano, Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research. ,vol. 60, pp. 4959- 4967 ,(2000)
Selma Ugurel, Gunter Rappl, Wolfgang Tilgen, Uwe Reinhold, Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival Journal of Clinical Oncology. ,vol. 19, pp. 577- 583 ,(2001) , 10.1200/JCO.2001.19.2.577
M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, N. Thatcher, Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Journal of Clinical Oncology. ,vol. 18, pp. 158- 166 ,(2000) , 10.1200/JCO.2000.18.1.158
Ronnie Tung-Ping Poon, Sheung-Tat Fan, John Wong, Clinical Implications of Circulating Angiogenic Factors in Cancer Patients Journal of Clinical Oncology. ,vol. 19, pp. 1207- 1225 ,(2001) , 10.1200/JCO.2001.19.4.1207
Jonathan P. S. Knisely, James B. Yu, Jaclyn Flanigan, Mario Sznol, Harriet M. Kluger, Veronica L. S. Chiang, Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival Journal of Neurosurgery. ,vol. 117, pp. 227- 233 ,(2012) , 10.3171/2012.5.JNS111929
Anna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, Mario Santinami, Pier Francesco Ferrucci, Diana Giannarelli, Antonella Marasco, Licia Rivoltini, Ester Simeone, Stefania VL Nicoletti, Ester Fonsatti, Diego Annesi, Paola Queirolo, Alessandro Testori, Ruggero Ridolfi, Giorgio Parmiani, Michele Maio, Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Lancet Oncology. ,vol. 13, pp. 879- 886 ,(2012) , 10.1016/S1470-2045(12)70324-8
Neal Ready, Frederick Aronson, Harold Wanebo, Theresa Kennedy, A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. American Journal of Clinical Oncology. ,vol. 28, pp. 479- 484 ,(2005) , 10.1097/01.COC.0000164006.72694.1B
Helmut Erhard, Frank J. R. Rietveld, Margarethe C. van Altena, Eva-B. Br??cker, Dirk J. Ruiter, Robert M.W. de Waal, Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis Melanoma Research. ,vol. 7, pp. 19- 26 ,(1997) , 10.1097/00008390-199708001-00005
Ruggero Ridolfi, Antonella Romanini, Vanna Chiarion Sileni, Maria Michiara, Michele Guida, Guido Biasco, Paola Poletti, Laura Amaducci, Maurizio Leoni, Alessandra Ravaioli, Italian Melanoma Intergroup, None, Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Research. ,vol. 14, pp. 295- 299 ,(2004) , 10.1097/01.CMR.0000136711.75287.55